The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence
Abstract
One of the most important of the secondary causes of osteoporosis is chronic exposure to glucocorticoids, which are used for an extraordinarily large number of disorders. The adverse effects of hypercortisolism on bone metabolism were recognized more than half a century ago (1). Today, glucocorticoid exposure in the context of medicinal use has become far more common than excess endogenous exposure (Cushing’s syndrome). Glucocorticoid-induced osteoporosis (GIO) is the third most common cause of osteoporosis, trailing only postmenopausal and age-related osteoporosis (2). As many as 50% of individuals on chronic glucocorticoid therapy will suffer an osteoporotic fracture (3). Recently, a large-scale retrospective cohort study by Van Staa et al. (4) in England clearly demonstrated that fracture risk is increased across virtually the entire dosage range of oral glucocorticoids. A large number of subjects with a history of glucocorticoid exposure (n = 244,235) were matched to the same number of control patients who had no history of glucocorticoid exposure. The average age of the subjects was 57 yr; respiratory diseases were the common indication for therapy, being prescribed in 40% of the patients (4). Referent to nonglucocorticoid users, subjects with a history of glucocorticoid therapy had significantly greater risk for fractures at the spine (rr = 2.6), the hip (rr = 1.6), and at any nonvertebral site (rr = 1.3). The magnitude of the fracture risk was directly related to dosage, with subjects receiving as little as 2.5 mg of prednisolone at significantly greater risk than control subjects (4). Bone loss from glucocorticoid use was also found to occur rapidly, within the first 3 months of treatment. A similarly precipitous loss of bone mass has also been observed prospectively when glucocorticoids are used in the setting of organ transplantation (5, 6), and in other clinical situations (7–10). Even inhaled steroids have been implicated as a cause of bone loss (11, 12). The cardinal feature of GIO on skeletal dynamics is a reduction in bone formation. Bone formation is inhibited, in part, through a decrease in osteoblast life span and function. Histomorphometric studies demonstrate a marked reduction in indices of bone formation, such as reduced mineral apposition rate and prolonged mineralization lag time. The amount of bone that is replaced in each remodeling cycle can be reduced by as much as 30% (13–17). Biochemical markers of bone formation, osteocalcin and bone-specific alkaline phosphatase, are suppressed. In addition to this primary suppressive effect on bone formation, glucocorticoids also induce an early phase of accelerated bone resorption (18). Osteoclast number and activity increase, along with an increase in the fraction of eroded bone surface (14, 15). Biochemical markers of bone resorption, urinary N-telopeptide and pyridinoline cross-link excretion, rise during early glucocorticoid exposure (17, 19, 20). This early phase of glucocorticoid use, therefore, can be associated with rapid bone loss due to both reduced bone formation and accelerated bone resorption. With continued use of glucocorticoids, the rapid rate of osteoclast-mediated bone resorption slows (14), but suppression of bone formation continues as the dominant skeletal dynamic. Thus, bone loss is progressive because bone resorption chronically exceeds bone formation. Although bone loss due to glucocorticoid use tends to be diffuse, the axial skeleton is targeted preferentially. The cancellous bones of the vertebral spine are typically affected, whereas cortical bone sites of the appendicular skeleton (i.e. forearm) are affected to a lesser extent (21, 22). Spontaneous fractures of the vertebrae or ribs are common complications of GIO (23). The pathogenesis of GIO is multifactorial (Fig. 1; Ref 24). Reduction of gonadal hormones is an important mechanism through the inhibitory effects of glucocorticoids on the pituitary gonadotropins (19). Glucocorticoids blunt the secretion of LH in response to GnRH in men and women (25, 26), inhibit the action of FSH, and reduce gonadal sex steroid production (27–31). In one study, asthmatic men treated with prednisone at an average daily dose of 12 mg had significantly lower free and total testosterone levels and higher LH and FSH levels than age-matched control subjects (29). Similarly, estrogen levels decline with glucocorticoid administration (30, 31). The classical pathophysiology of GIO. The shaded area is the focus of attention in this paper. However, the adverse effects of glucocorticoids on bone are not mediated exclusively by sex-steroid deficiency (29, 32, 33). Other proposed mechanisms for GIO include the effects of glucocorticoids on the expression of locally produced growth factors and related proteins (18). Prolonged exposure to high levels of glucocorticoids results in reduced production of IGF-I, a trophic factor for bone, as well as alterations in IGF-binding proteins in osteoblas
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Carbonare, L. D., Arlot, M. E., Chavassieux, P. M., Roux, J. P., Portero, N. R., & Meunier, P. J. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.1.97 · Cited by 309
Effects of inhaled glucocorticoids on bone density in premenopausal women.
Israel, E., Banerjee, T. R., Fitzmaurice, G. M., Kotlov, T. V., LaHive, K., & LeBoff, M. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002304 · Cited by 303
Reversible gonadotropin Deficiency in Male Cushing's Dusease
LUTON, J.-P., THIEBLOT, P., VALCKE, J.-C., MAHOUDEAU, J. A., & BRICAIRE, H. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-3-488 · Cited by 202
Cited by
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
Self-citationGlucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Chotiyarnwong, P., & McCloskey, E. V. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0341-0 · Cited by 489
Metadata
- Authors
- Rubin, M. R., & Bilezikian, J. P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-09
- Volume
- 87
- Issue
- 9
- Pages
- 4033-4041
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2048730055
- Cited by
- 193
- References
- 6
- FWCI
- 16.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence. https://app.cochat.ai/papers/10.1210/jc.2002-012101
- The paper
- Rubin, M. R., & Bilezikian, J. P. (2002). The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2002-012101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.